Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: An overview of preclinical and clinical findings

Abstract

Cholinergic receptor manipulations have an effect on cognition, emotion, and brain electrical activity as measured by EEG. Changes in cognition can result from direct cholinergic receptor manipulation or from cholinergically induced changes in vigilance or affective state.

Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review

“…The third cholinergic subsystem arises from a collection of cholinergic interneurons in the striatum, which provides a dense local innervation. These interneurons contribute about 1-3% of the striatal neurons and interact with the rich dopaminergic innervation of the striatum (Graef et al, 2011).…”

Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review

“…The third cholinergic subsystem arises from a collection of cholinergic interneurons in the striatum, which provides very dense local innervation. These interneurons contribute about 1-3% of the striatal neurons and interact with the rich dopaminergic innervation of the striatum [106].…”

“…The metabotropic G protein-coupled muscarinic ACh receptors (mAChRs) belong to the multigene family of serotonin, norepinephrine and dopamine receptors and play an important role for memory functions [106]. The ionotropic cys-loop ligand-gated nicotinic ACh receptor channels (nAChRs) are members of the supergen family that comprise glycine, GABA and 5HT-3 receptors and appear to be more relevant for attentional functions (particularly sustained attention) than muscarinic receptors, with stronger evidence pointing to the involvement of the α4β2 subtype [107].…”

Different patterns of 5-HT receptor and transporter dysfunction in neuropsychiatric disorders – a comparative analysis of in vivo imaging findings

“…Among the neurotransmitters implicated in AD, MDD and SZ are catecholamines (AD, Stein et al, 2002;MDD, Willner, 1983;SZ, Seeman and Lee, 1975), glutamate (AD, Carlsson, 2001;MDD, Mitchell and Baker, 2010; SZ, Konradi and Heckers, 2003), acetylcholine (AD, Graef et al, 2011;MDD, Mineur and Picciotto, 2010;SZ, Hajós and Rogers, 2010) and γ-aminobutyric acid ([GABA]; AD, Nuss, 2015;MDD, Pehrson and Sanchez, 2015;SZ, Taylor and Tso, 2014).…”